Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04472429
Title Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation

anal squamous cell carcinoma


Carboplatin + Paclitaxel

Carboplatin + Paclitaxel + Retifanlimab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL

No variant requirements are available.